Home » Health » An American team focuses its efforts on a new experimental Alzheimer’s vaccine

An American team focuses its efforts on a new experimental Alzheimer’s vaccine

The Gates Biomanufacturing Facility at the Anschutz Medical Campus of the University of Colorado (United States) has announced the completion of the production process of an experimental recombinant protein against Alzheimer’s disease that will be tested as a vaccine in clinical trials. This vaccine, known as AV-1980R, can be used to …


The Gates Biomanufacturing Facility at the Anschutz Medical Campus of the University of Colorado (United States) has announced the completion of the production process of an experimental recombinant protein against Alzheimer’s disease that will be tested as a vaccine in clinical trials.

This vaccine, known as AV-1980R, can be used for phase 1 and 2 human clinical trials, and was funded with funds provided by the National Institute on Aging of the United States (NIA, for its acronym in English. ). .

Abnormal aggregation of Tau in neurofibrillary tangles is the hallmark of several tauopathiesneurodegenerative diseases including Alzheimer’s disease.

Until now, Alzheimer’s treatments have focused primarily on treating patients who are already sick. The AV-1980R vaccine targets Alzheimer’s disease and other neurodegenerative disorders associated with Tau aggregation, providing extraordinary levels of antibody protection against harmful forms of the Tau protein that can cause disease.

“But once the disease begins and the neurons are damaged, it becomes impossible to stop the disease. Now, with the help of the AV-1980R, we have a highly immunogenic preventive vaccine that could induce significant levels of antibodies that inhibit the aggregation of the disease. Tau in people without cognitive problems who are at risk for Alzheimer’s and block the onset of the disease“, commented Michael Agadjanyan, vice president of the California Institute for Molecular Medicine, who will conduct the clinical trials.

It is becoming increasingly clear that targeting Alzheimer’s amyloid deposits and forming them is not, in itself, an effective approach to halting or reversing Alzheimer’s disease.. New therapies are needed. “The development and production of a Tau vaccine is one of the most promising approaches and could be used alone or in combination with anti-amyloid antibodies currently undergoing clinical trials.“, detailed the doctor Huntington Potter, Professor of Neurology, Director of the Alzheimer’s Disease Program at the Linda Crnic Institute for Down Syndrome and Director of the Center for Alzheimer’s and Cognition at the University of Colorado.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.